RayzeBio Company Overview, Contact Details & Competitors

Q: What is RayzeBio's official website and social media links?

RayzeBio's official website is rayzebio.com. RayzeBio has social profiles on LinkedIn.

Q: How many employees does RayzeBio have currently?

RayzeBio has approximately 226 employees.

Q: What technology does RayzeBio use?

RayzeBio's tech stack includes Twemoji, ICP-MS, Cloudflare, Apple iCloud Mail, Google Analytics.

Insights

Gathering insights about RayzeBio…

Similar companies to RayzeBio

RayzeBio Tech Stack

RayzeBio uses 8 technology products and services including ICP-MS, RSS, SAP, and more. Explore RayzeBio's tech stack below.

ICP-MS
Advanced Analytics And Data Science
RSS
Content Management System
SAP
Customer Relationship Management
Twemoji
Font Scripts
Underscore.js
Javascript Libraries
Microsoft
Miscellaneous
WP Engine
Platform As A Service
Cloudflare Bot Management
Security

Media & News

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating pat.
Feb 26, 2024 | www.businesswire.com
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the “Offer”) to acquire all of the outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the “Expiration Time”). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiratio.
Feb 23, 2024 | www.businesswire.com
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting peri.
Feb 12, 2024 | www.businesswire.com
IPO watch 2024: Which new stocks will hit the market?
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
Jan 08, 2024 | www.marketbeat.com
Cramer names biopharma companies to watch as industry mergers start to pile up
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
Jan 05, 2024 | www.cnbc.com
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RayzeBio, Inc. (NasdaqGM: RYZB) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of RayzeBio will receive $62.50 in cash for each share of RayzeBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq.
Dec 31, 2023 | www.businesswire.com
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday.
Dec 27, 2023 | www.marketwatch.com

RayzeBio's Email Address Formats

RayzeBio uses at least 1 format(s):

RayzeBio Email Formats	Example	Percentage
FLast@rayzebio.com	JDoe@rayzebio.com	42%
Last@rayzebio.com	Doe@rayzebio.com	8%
FLast@rayzebio.com	JDoe@rayzebio.com	42%
Last@rayzebio.com	Doe@rayzebio.com	8%

Frequently Asked Questions

What is RayzeBio's stock symbol?

RayzeBio is a publicly traded company; the company's stock symbol is RYZB.

What is RayzeBio's official website and social media links?

RayzeBio's official website is rayzebio.com and has social profiles on LinkedIn Crunchbase.

What is RayzeBio's SIC code NAICS code?

RayzeBio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does RayzeBio have currently?

As of December 2025, RayzeBio has approximately 226 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Chief Medical Officer: A. H.Head Of Cmc, Rayzebio China: J. W.Owner: A. A.. Explore RayzeBio's employee directory with LeadIQ.

What industry does RayzeBio belong to?

RayzeBio operates in the Biotechnology Research industry.

What technology does RayzeBio use?

RayzeBio's tech stack includes ICP-MSRSSSAPTwemojiUnderscore.jsMicrosoftWP EngineCloudflare Bot Management.

What is RayzeBio's email format?

RayzeBio's email format typically follows the pattern of FLast@rayzebio.com. Find more RayzeBio email formats with LeadIQ.

How much funding has RayzeBio raised to date?

As of December 2025, RayzeBio has raised $160M in funding. The last funding round occurred on Sep 13, 2022 for $160M.

When was RayzeBio founded?

RayzeBio was founded in 2020.

Insights

Similar companies to RayzeBio

OncoMyx Therapeutics

Sarepta Therapeutics

Jasper Therapeutics

Ember Therapeutics

AsclepiX Therapeutics

EnClear Therapies

RayzeBio Tech Stack

Media & News

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

IPO watch 2024: Which new stocks will hit the market?

Cramer names biopharma companies to watch as industry mergers start to pile up

RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB

Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target

RayzeBio's Email Address Formats

Frequently Asked Questions

What is RayzeBio's stock symbol?

What is RayzeBio's official website and social media links?

What is RayzeBio's SIC code NAICS code?

How many employees does RayzeBio have currently?

What industry does RayzeBio belong to?

What technology does RayzeBio use?

What is RayzeBio's email format?

How much funding has RayzeBio raised to date?

When was RayzeBio founded?

RayzeBio

Company Overview

Media & News

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?